Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.63 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 8/20 | 0.50 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203855 | 0.86 | ESR1 (0.65) | ESR2HSD17B1ESR1MMP2MMP3 | |
| SCHEMBL7206316 | 0.82 | HSD17B1 (0.51) | ESR2HSD17B1ESR1WEE1ALDH1A1 | |
| SCHEMBL7205812 | 0.79 | ESR2 (0.55) | ESR2ESR1ALDH1A1MAPTHPGD | |
| SCHEMBL4091247 | 0.73 | HSD17B1 (0.81) | ESR2HSD17B1ESR1MMP2MMP3 | |
| SCHEMBL4101247 | 0.70 | HSD17B1 (1.00) | ESR2HSD17B1ESR1WEE1MMP2 | |
| SCHEMBL10138245 | 0.68 | SLC22A12 (0.55) | HSD17B1 | |
| SCHEMBL7205506 | 0.67 | ESR1 (0.57) | ESR2ESR1ALDH1A1HPGDKDM4E | |
| SCHEMBL21994117 | 0.66 | MAPT (0.52) | HSD17B1ALDH1A1MAPTHPGDKIF11 | |
| SCHEMBL7204491 | 0.66 | MEN1 (0.50) | ESR2ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL4085842 | 0.65 | HSD17B1 (1.00) | ESR2HSD17B1ESR1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599921-B2 | Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives | NANODESIGN, INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | PALOMA PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | ESRRA, ESRRB, ESRRG | ESR2 4/4885HSD17B1 58/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.